Boston Biomedical Innovation Center (B-BIC) is a life sciences accelerator funded by the National Institutes of Health and our member institutions to increase the return on investment in research. We speed the translation of research technologies into products for doctors and their patients, for the good of society.
Our members are a consortium of academic medical centers in Boston including Brigham and Women’s Hospital, Harvard Medical School, Massachusetts General Hospital, and the Massachusetts Institute of Technology.
B-BIC provides funding for technology development and translational research, including regulatory, reimbursement, and business development aspects that are part of an overall commercialization strategy.
Community member post by Erica Lawlor and Cheryl Vaughan How can scientists whose careers were formed in an incentive system that cultivates competitive and territorial behaviors be helped to meet the expectations of collaborative research frameworks? A team-based approach that transcends disciplinary boundaries may be a tall order for scientists who “grew up” in a…Read More
Written by Carl Berke, PhD. Partner at the Partners Innovation Fund Thomas Edison famously remarked, “Invention is 1% inspiration and 99% perspiration”. The Wizard of Menlo Park was a prolific inventor who never left his lab, but his intellectual property was adopted by a plethora of companies who translated his technology into products that delighted…Read More
Over the course of 2019, our coaches and staff broke down the B-BIC application process to provide you with expert advice on all the of the questions we ask you to answer when applying for our program. For those who are not applying yet, the B-BIC proposal has many similarities to a business plan, which…Read More
Written by Erin McKenna, B-BIC Deputy Director There are multiple frameworks out there that outline the process for developing promising biomedical research into a range of innovative solutions – pharmaceuticals, biologics, medical devices, and diagnostics. Many of these processes leverage concepts that come from regulations developed by the FDA, the European Commission and others to…Read More
Written by Paul Tessier A common refrain heard by healthcare entrepreneurs is that they should focus on satisfying an “unmet clinical need,” however there is no universal definition of the phrase, “unmet clinical need.” Even established companies and public healthcare agencies, who use the concept of an unmet clinical need to assist in developing product…Read More
Contributed by Ilsa Webeck B-BIC Skills Development Expert Developing Innovative Strategies for Leading Edge Medical Technology Companies “I have an idea. A great idea. I mean, it’s an “I can’t believe no one has thought of this before” idea. The market for this product is going to be enormous.” In conversations with innovators spanning devices, biologics,…Read More
Contributed by Erin McKenna, Deputy Director of B-BIC & Paul Tessier, B-BIC Coach Once you understand the unmet clinical need your technology can address and have connected that need with a solid business opportunity, the next thing to be considered is to understand the development path for the product you want to create. Outlining the…Read More
Technology in Search of an Application Part II of the Specialist Series: The Road to Commercialization: Challenges and Opportunities Written by John Randle Development models always start with addressing clinical needs, but scientific discoveries and technological advances typically happen independently from solving clinical problems. This article will explore ways you can ensure that you are…Read More
We are thrilled to share with you a new web video we are releasing that highlights our ‘Commercialization Coaches’ and other services that are ways B-BIC successfully differentiates from other grants. Kantum Pharma, dedicated to the prevention and treatment of Acute Kidney Injury, received its first B-BIC Pilot grant in 2017.Read More
By Jay Knowles Partner, Innovation Many venture capitalists look for opportunities to invest in a company or a project such that if it reaches a certain inflection point, that company will become significantly more valuable, and what it will cost to get it to that point. As an example, investors often like to see how…Read More
By Lesley Watts When describing the financial support necessary to develop a technology, the first step is to be clear about the scope of the work you are addressing, as no single source of funding will be able to support all of the associated R&D costs. Anyone who is assessing your project plan will want…Read More
Co-authored by Erin McKenna, B-BIC Deputy Director & Ron Blackman, B-BIC Sr. Project Manager. When considering a development path needed to move technology to the clinic and beyond, it’s essential to address two questions: Who will support the development of your technology, and what will they want to see to believe it can be commercialized? Who Will Support…Read More
Contributed by Ed Berger Principal Larchmont Strategic Advisors Reimbursement strategy counsel to companies across the life sciences spectrum A basic understanding of the healthcare reimbursement system is an important success factor for any entrepreneur developing a new medical product. Reimbursement is critical to opportunity assessment, business plan development, investor due diligence, and commercial success. The…Read More
Contributed by Lesley Watts, Director of B-BIC Operations & Finance Intellectual property is the product of a person’s creativity and it can take several forms including patents, copyright, trademarks, and trade secrets. Patents play a key role in innovation and economic development, particularly in the life sciences, because they allow the patent holder to capture the…Read More
WATCH: B-BIC’s Work With Platelet Biogenesis One of B-BIC’s first grant recipients was Jonathan Thon, a researcher based at Brigham and Women’s Hospital. Jonathan and his team had been researching two technologies necessary for producing platelets outside of the body. They had achieved promising results that demonstrated a microfluidic platform could simulate bone marrow physiological…Read More